Ladostigil hemitartrate is primarily investigated for its neuroprotective properties, making it a potential candidate for treating neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease. It functions as a dual inhibitor of acetylcholinesterase and monoamine oxidase-B, which helps in enhancing cognitive functions and reducing oxidative stress in the brain. Additionally, its anti-inflammatory and antioxidant effects are being studied for their role in slowing the progression of these diseases. Research also explores its potential in improving memory and learning abilities in aging populations. Clinical trials are ongoing to evaluate its efficacy and safety in human subjects.